The price of Biogen’s new drug, Vumerity, has been heavily criticized by the National Multiple Sclerosis Society (NMSS), STAT reports.
“Vumerity is an efficacious and tolerable treatment option for people with relapsing MS, but being priced only $500 lower than the least expensive oral disease modifying treatment, does not show the commitment to affordable access that we had hoped,” the society said.
The drug carries a $88,000 per year price tag.
To read the full report on STAT, click here. (Paid subscription required)